Multiple pharmaceutical companies enjoy a "bumper harvest," with 20 companies' net profits doubling last year

Securities Times Reporter Zang Xiaosong

Lisheng Pharmaceutical (002393) released its annual report on the evening of March 24. In 2025, the company achieved operating revenue of 1.392 billion yuan, a year-on-year increase of 4.18%; net profit attributable to shareholders was 416 million yuan, a year-on-year increase of 125.59%; basic earnings per share were 1.62 yuan. The company plans to convert every 10 shares into 2 shares and distribute a cash dividend of 6 yuan (tax included).

In 2025, Lisheng Pharmaceutical will deploy a “dual-wheel drive” strategy of “industry + capital,” systematically promoting the company’s industrial system toward high-end, intelligent, and green development. During the reporting period, the company advanced the synergy between fund and direct investment, and cooperated with CCB Equity to establish a new pharmaceutical and health-focused fund with an initial scale of 500 million yuan, creating a differentiated fund cluster. Meanwhile, the company continued to explore high-quality investment targets along the upstream and downstream of the industry chain, steadily advancing project reserves and screening work to solidify resources for future industry expansion.

In 2025, China’s pharmaceutical industry entered a new stage of “quality improvement, supply assurance, cost control, and correction,” characterized by “slowing growth, structural optimization, innovation-led development, and compliance.” Policy guidance, market demand, and technological innovation are deeply intertwined, accelerating the restructuring of the industry landscape. This presents new challenges for industry development but also creates structural opportunities for leading enterprises with core competitiveness.

According to data from the National Bureau of Statistics, in 2025, the operating revenue of China’s pharmaceutical manufacturing industry above designated size reached 2.487 trillion yuan, a decrease of 1.2% year-on-year; total profit was 349 billion yuan, an increase of 2.7%, showing a healthy trend of “slight revenue decline and stabilized profits.”

The Securities Times found that as of the evening of March 24, 173 pharmaceutical companies had disclosed their 2025 “performance reports,” of which 125 companies reported profits, and 20 companies saw net profit increases of over 100%.

Earlier, on the evening of March 23, WuXi AppTec (603259) released its 2025 annual performance report: during the reporting period, the company achieved operating revenue of 45.456 billion yuan, a year-on-year increase of 15.84%; net profit attributable to shareholders was 19.151 billion yuan, a year-on-year increase of 102.65%.

Teva Pharmaceutical (002728) achieved revenue of 925 million yuan last year, a 34.42% increase; net profit attributable to shareholders was 81.67 million yuan, a 298.5% increase. The company plans to distribute a cash dividend of 1.5 yuan (tax included) for every 10 shares to all shareholders.

Sansen Guojian (688336) previously disclosed its performance brief, showing that in 2025, the company achieved operating revenue of 4.199 billion yuan, an increase of 251.81% compared to the previous year; net profit attributable to the parent company was 2.939 billion yuan, a 317.09% increase. The significant growth in performance compared to the previous year was mainly due to the company reaching an important cooperation with Pfizer during the reporting period, receiving an initial licensing payment of approximately 2.89 billion yuan from Pfizer for Project 707, and recognizing this income accordingly.